FDA Approves Xpovio Triple Combo for Previously Treated Myeloma

FDA Approves Xpovio Triple Combo for Previously Treated Myeloma

281839

FDA Approves Xpovio Triple Combo for Previously Treated Myeloma

The U.S. Food and Drug Administration (FDA) has approved a triple combination of Xpovio (selinexor) plus Velcade (bortezomib) and low-dose dexamethasone for the treatment of people with multiple myeloma who received at least one line of therapy. The approval, which comes three months ahead of deadline, was based on promising data from the BOSTON Phase 3 trial (NCT03110562), in which the triple combo significantly extended patients’ lives without disease worsening, increased response rates, and prolonged…

You must be logged in to read/download the full post.